GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Cyclically Adjusted PB Ratio

ProPhase Labs (ProPhase Labs) Cyclically Adjusted PB Ratio : 2.03 (As of Jun. 07, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Cyclically Adjusted PB Ratio?

As of today (2024-06-07), ProPhase Labs's current share price is $4.64. ProPhase Labs's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.29. ProPhase Labs's Cyclically Adjusted PB Ratio for today is 2.03.

The historical rank and industry rank for ProPhase Labs's Cyclically Adjusted PB Ratio or its related term are showing as below:

PRPH' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.9   Med: 2.06   Max: 13.79
Current: 2.09

During the past years, ProPhase Labs's highest Cyclically Adjusted PB Ratio was 13.79. The lowest was 0.90. And the median was 2.06.

PRPH's Cyclically Adjusted PB Ratio is ranked worse than
54.07% of 135 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.01 vs PRPH: 2.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ProPhase Labs's adjusted book value per share data for the three months ended in Mar. 2024 was $2.486. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.29 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProPhase Labs Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ProPhase Labs's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Cyclically Adjusted PB Ratio Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.68 7.90 4.82 5.01 2.04

ProPhase Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.78 3.45 2.01 2.04 2.82

Competitive Comparison of ProPhase Labs's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, ProPhase Labs's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Cyclically Adjusted PB Ratio falls into.



ProPhase Labs Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ProPhase Labs's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.64/2.29
=2.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ProPhase Labs's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.486/131.7762*131.7762
=2.486

Current CPI (Mar. 2024) = 131.7762.

ProPhase Labs Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.705 100.560 0.924
201409 0.681 100.428 0.894
201412 0.674 99.070 0.897
201503 0.590 99.621 0.780
201506 0.512 100.684 0.670
201509 0.588 100.392 0.772
201512 0.517 99.792 0.683
201603 0.439 100.470 0.576
201606 0.373 101.688 0.483
201609 0.383 101.861 0.495
201612 0.349 101.863 0.451
201703 2.958 102.862 3.789
201706 2.885 103.349 3.679
201709 2.949 104.136 3.732
201712 2.861 104.011 3.625
201803 2.976 105.290 3.725
201806 1.780 106.317 2.206
201809 1.707 106.507 2.112
201812 1.429 105.998 1.777
201903 1.359 107.251 1.670
201906 1.267 108.070 1.545
201909 1.245 108.329 1.514
201912 0.970 108.420 1.179
202003 0.918 108.902 1.111
202006 0.940 108.767 1.139
202009 0.927 109.815 1.112
202012 0.910 109.897 1.091
202103 3.475 111.754 4.098
202106 3.150 114.631 3.621
202109 3.083 115.734 3.510
202112 3.786 117.630 4.241
202203 4.291 121.301 4.662
202206 4.335 125.017 4.569
202209 4.238 125.227 4.460
202212 3.925 125.222 4.130
202303 3.557 127.348 3.681
202306 3.518 128.729 3.601
202309 3.127 129.860 3.173
202312 2.737 129.419 2.787
202403 2.486 131.776 2.486

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProPhase Labs  (NAS:PRPH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ProPhase Labs Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136

ProPhase Labs (ProPhase Labs) Headlines

From GuruFocus

DSS Inc. Issues Letter to Shareholders

By Marketwired 10-12-2023